Healthcare >> CEO Interviews >> October 26, 2004
ANTHONY WEIR is Chief Financial Officer of Vernalis Plc. Mr. Weir has a
degree in Mathematics from Oxford University and is a Fellow of the
Institute of Chartered Accountants. Following qualification he advised a
variety of businesses as a financial consultant and joined British
Biotech in 1990 as Chief Accountant and Company Secretary. In April 1999
he was promoted to the Board with responsibility for finance, corporate
communications, legal and company secretariat, facilities and IT. In the
last 18 months, he was instrumental in the establishment of Vernalis Plc
from the combination of British Biotech, Ribo Targets and Vernalis Group
and he continues as CFO of Vernalis. He has worked closed with the Chief
Executive to establish a sound financial basis for Vernalis through
securing three recent collaborations with Endo, Biogen Idec and
Novartis. Included within this was the provision of a $50 million five-
year loan facility from Endo. Profile
TWST: Can you start with a history and overview of Vernalis?Mr. Weir: Vernalis was been created from the combination in 2003 of
three UK-based, research and development biotech companies.